Penn Capital Management’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-266,167
Closed -$15.3M 155
2024
Q3
$15.3M Sell
266,167
-34,503
-11% -$1.98M 1.4% 24
2024
Q2
$15.8M Buy
300,670
+28,074
+10% +$1.23M 1.5% 12
2024
Q1
$11.1M Sell
272,596
-6,944
-2% -$260K 0.99% 53
2023
Q4
$10.4M Sell
279,540
-45,167
-14% -$1.7M 0.95% 54
2023
Q3
$12.5M Buy
324,707
+38,217
+13% +$1.57M 1.28% 24
2023
Q2
$10.3M Buy
286,490
+768
+0.3% +$26.2K 1% 45
2023
Q1
$11M Sell
285,722
-801
-0.3% -$37.6K 1.11% 42
2022
Q4
$16.4M Sell
286,523
-29,061
-9% -$1.49M 1.67% 4
2022
Q3
$12.5M Buy
315,584
+15,759
+5% +$697K 1.4% 18
2022
Q2
$13.2M Buy
299,825
+74,976
+33% +$3.24M 1.42% 19
2022
Q1
$8.34M Sell
224,849
-54,574
-20% -$1.94M 0.86% 54
2021
Q4
$11.3M Sell
279,423
-10,971
-4% -$410K 1.14% 24
2021
Q3
$11.8M Buy
290,394
+13,482
+5% +$564K 1.19% 20
2021
Q2
$12.6M Buy
276,912
+7,995
+3% +$354K 1.22% 14
2021
Q1
$11.2M Buy
268,917
+27,555
+11% +$1.26M 1.17% 20
2020
Q4
$10.3M Sell
241,362
-51,208
-18% -$1.84M 1.3% 11
2020
Q3
$7.76M Buy
292,570
+2,483
+0.9% +$69.1K 0.98% 18
2020
Q2
$7.84M Buy
290,087
+5,944
+2% +$134K 1.02% 16
2020
Q1
$5.12M Buy
+284,143
New +$5.39M 0.84% 35

Other funds holding HALO

Penn Capital Management's HALO Position: Q4 2024 in Review

Penn Capital Management sold out of Halozyme (HALO) in Q4 2024, closing a stake of 266,167 shares — an estimated $15.3M sold.

Penn Capital Management first reported a position in HALO in Q1 2020 and held it in 19 quarters. The position peaked at $16.4M in Q4 2022. 508 funds tracked by Wall St. Rank hold HALO as of Q4 2024.

  • Penn Capital Management reported no remaining Halozyme position as of Q4 2024 after selling out during the quarter.
  • Penn Capital Management sold 266,167 Halozyme shares in Q4 2024, an estimated $15.3M.
  • Penn Capital Management first reported a position in Halozyme in Q1 2020 and held it in 19 quarters.
  • Penn Capital Management's Halozyme position peaked at $16.4M in Q4 2022.
  • 508 funds tracked by Wall St. Rank held Halozyme as of Q4 2024.

Based on Penn Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.